Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 13, 2026. The filing serves to disclose the Company's financial results for the second quarter ended June 30, 2026, and certain other corporate developments. The Company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report explicitly states that the financial results are detailed in a press release dated August 13, 2026, which is incorporated by reference as Exhibit 99.1. Consequently, no quantitative financial metrics can be extracted from the provided 8-K text alone.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis of the second quarter 2026 results against previous periods.
Guidance, Outlook, and Risks
The 8-K text does not include specific guidance, outlook, management commentary, or risk factors. It notes that the information is furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) but is not deemed "filed" for purposes of Section 18 of the Exchange Act. The document contains no admission regarding the materiality of the information disclosed solely under Regulation FD.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for actual Q2 2026 financial figures.
- Verify the specific corporate developments mentioned in the press release.
- Confirm the Company's status as an emerging growth company and any associated reporting implications.
- Check for any subsequent filings that may incorporate the press release data by reference.